A-Labs Capital V Corp.
(A Capital Pool Company)

Condensed Interim Financial Statements

(Expressed in Canadian Dollars)

(Unaudited)

For the Three and Six Months Ended June 30, 2021

Notice to Reader

The accompanying unaudited condensed interim financial statements of A-Labs Capital V Corp. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim financial statements have not been reviewed by the Company's auditors.

A-Labs Capital V Corp.
Condensed Statement of Financial Position
(Expressed in Canadian Dollars)
(Unaudited)

	June 30, 2021	December 31, 2020
Assets		
Current		
Cash and cash equivalents (Note 4)	**$ 105,249**	$ 31,684
Prepaid expenses	**-**	1,750
	$ 105,249	$ 33,434
Liabilities		
Current		
Accounts payable	**$ 33,174**	$ 20,498
	33,174	20,498
Shareholders' Equity		
Capital stock (Note 5)	**195,064**	100,064
Deficit	**(122,989)**	(87,128)
	72,075	12,936
	$ 105,249	$ 33,434

Nature of Operations (Note 1)
Subsequent Events (Note 8)

Approved by the Board

"(signed) Rita Alter" — Director

"(signed) Hillar Lilles" — Director

A-Labs Capital V Corp.

Condensed Statement of Loss and Comprehensive Loss

(Expressed in Canadian Dollars)

(Unaudited)

	For the Three Month Period Ended June 30, 2021	For the Three Month Period Ended June 30, 2020	**For the Six Month Period Ended June 30, 2021**	For the Six Month Period Ended June 30, 2020
Expenses				
Operating expenses	**$ 800**	$ 7,876	**$ 6,050**	$ 9,376
Professional fees	**16,175**	14,000	**29,811**	31,223
Net and comprehensive loss for the period	**$ 16,975**	$ 21,876	$ 35,861	$ 40,599

Loss per Share				
Basic and diluted loss for the period	**$ 0.01**	$ 0.01	**$ 0.01**	$ 0.02
Weighted average number of shares outstanding (Note 5)	**3,426,281**	2,001,281	**2,713,781**	2,001,281

A-Labs Capital V Corp.
Condensed Interim Statement of Changes in Shareholders' Equity
(Expressed in Canadian Dollars)
(Unaudited)

	Number of Shares	Amount	Contributed Surplus	Deficit	Total
Balance, December 31, **2019**	2,001,281	$ 100,064	$ -	$ (52,021)	$ 48,043
Net loss for the period	-	-	-	(40,599)	(40,599)
Balance, June 30, 2020	**2,001,281**	**$ 100,064**	-	**(92,620)**	**$ 7,444**
Balance, December 31, **2020**	**2,001,281**	**$ 100,064**	**$ -**	**$ (87,128)**	**$ 12,936**
Shares issued in private placement	1,900,000	95,000	-	-	95,000
Net loss for the period	-	-	-	(35,861)	(35,861)
Balance, June 30, 2021	**3,901,281**	**$ 195,064**	**$ -**	**$ (122,989)**	**$ 72,075**

A-Labs Capital V Corp.
Condensed Interim Statement of Cash Flows
(Expressed in Canadian Dollars)
(Unaudited)

	For the Six Month Period Ended June 30, 2021	For the Six Month Period Ended June 30, 2020
Cash provided by (used in)		
Operating Activities		
Net loss for the period	**$ (35,861)**	$ (40,599)
Net changes in non-cash working capital		
Accounts payable and accrued liabilities	**12,676**	16,500
Cash (used in) operating activities	**(23,185)**	(24,099)
Financing Activity		
Issuance of capital stock	**95,000**	-
Net change in cash	**71,815**	(24,099)
Cash, beginning of period	**33,434**	56,171
Cash, end of period	**$ 105,249**	$ 32,072

1. NATURE OF OPERATIONS

A-Labs Capital V Corp. (the "Company") was incorporated by a Certificate of Incorporation issued pursuant to the provisions of the Canada Business Corporations Act on November 29, 2018. The registered office is located at 5255 Yonge Street, Suite 1110, Toronto, Ontario M2N 6P4.

The Company intends to be classified as a Capital Pool Company ("CPC") as defined in Policy 2.4 of the TSX Venture Exchange (the "Exchange"). The principal business of the Company will be to identify and evaluate assets or businesses with a view to potentially acquire them or an interest therein by completing a purchase transaction, by exercising of an option or by any concomitant transaction. The purpose of such an acquisition is to satisfy the related conditions of a qualifying transaction under the Exchange rules.

As at June 30, 2021, the Company has issued 3,901,281 common shares for gross proceeds of $195,064. On June 11, 2021, the Company filed a Prospectus for the distribution of a minimum of 2,000,000 common shares and a maximum of 5,000,000 common shares at a price of $0.10 per common share for gross proceeds of a minimum of $200,000 and a maximum of $500,000.

These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process offorced liquidation. The financial statements do not include adjustments to amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue operations.

As a CPC, the Company's principal business will be the identification and evaluation of assets, properties or businesses with a view to acquisition or participation therein subject, in certain cases, to shareholder approval and acceptance by the Exchange. Where an acquisition or participation is warranted (the "Qualifying Transaction"), additional funding may be required. The ability of the Company to fund its potential future operations and commitments is dependent upon the ability of the Company to obtain additional financing.

During the six months ended June 30, 2021, the Company incurred a loss in the amount of $35,861 (2020 - $40,599) and has a cumulative deficit of $122,989 (December 31, 2020 - $87,128). These conditions, along with the other matters described above, cast a material uncertainty on the Company's ability to continue as a going concern. Should the Company be unable to continue as a going concern, the adjustments may be material.

2. BASIS OF PRESENTATION

Statement of Compliance

These unaudited condensed interim financial statements have been prepared in accordance and compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Reporting Interpretations Committee, and IAS 34, Interim Financial Reporting.

These unaudited condensed interim financial statements should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2020. The accounting policies adopted in these condensed interim financial statements are consistent with those disclosed in the Company's audited financial statements for the year ended December 31, 2020. Notes to Financial Statements

2. BASIS OF PRESENTATION (Cont'd)

These condensed interim financial statements were authorized for issuance by the Board of Directors on August 30, 2021.

Basis of Measurement

These condensed interim financial statements are presented in Canadian dollars, which is the Company's functional and presentation currency.

Significant Accounting Judgments, Estimates and Assumptions

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities. The estimates and associated assumptions are based on anticipations and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

3. SIGNIFICANT ACCOUNTING POLICIES

Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial assets and liabilities are offset and the net amount is reported in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously.

i) Financial assets

The Company classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income (OCI) or through profit or loss); and
- those to be measured at amortized cost.

The classification depends on the Company's business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses are either recorded in profit or loss or OCI.

At present, the Company classifies all financial assets as held at amortized cost. Cash is classified as a financial asset.

3. SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

Financial Instruments (Cont'd)

i) Financial assets (cont'd)

At initial recognition, the Company measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVTPL are expensed in profit or loss. Financial assets are considered in theirentirety when determining whether their cash flows are solely payment of principal and interest.

Subsequent measurement of financial assets depends on their classification. There are three measurement categories under which the Company classifies its financial assets:

- Amortized cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. A gain or loss on a debt investment that is subsequently measured at amortized cost is recognized in profit or loss when the asset is derecognized or impaired. Interest income from these financial assets is included as finance income using the effective interest rate method.

- Fair value through OCI (FVOCI): Debt instruments that are held for collection of contractual cash flows and for selling the debt instruments, where the assets' cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains and losses, interest revenue, and foreign exchange gains and losses which are recognized in profit or loss. When the debt instrument is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains (losses). Interest income from these debt instruments is included as finance income using the effective interest rate method.

- Fair value through profit or loss: Assets that do not meet the criteria for amortized cost or FVOCI are measured at FVTPL. A gain or loss on an investment that is subsequently measured at FVTPL is recognized in profit or loss and presented net as revenue in the statement of loss and comprehensive loss in the period in which it arises.

ii) Financial liabilities

A financial liability is classified as at FVTPL if it is classified as held-for-trading or is designated as such on initial recognition. Directly attributable transaction costs are recognized in profit or loss as incurred. The fair value changes to financial liabilities at FVTPL are presented as follows: where the Company optionally designates financial liabilities at FVTPL the amount of change in the fair value that is attributable to changes in the credit risk of the liability is presented in OCI; and the remaining amount of the change in the fair value is presented in profit or loss. The Company does not designate any financial liabilities at FVTPL.

Other non-derivative financial liabilities are initially measured at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method.

At present, the Company classifies all of its financial liabilities as held at amortized cost. These financial liabilities are classified as current liabilities as the payment is due within 12 months.

(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

Impairment

Financial assets

At each balance sheet date, on a forward-looking basis, the Company assesses the expected credit losses associated with its financial assets carried at amortized cost and Fair Value through Other Comprehensive Income (“FVOCI”). The impairment methodology applied depends on whetherthere has been a significant increase in credit risk. The impairment model does not apply to FVTPL instruments. The expected credit losses are required to be measured through a loss allowance at an amount equal to the 12- month expected credit losses (expected credit losses that result from those default events on the financial instrument that are possible within 12 months after the reporting date) or full lifetime expected credit losses (expected credit losses that result from all possible default events over the life of the financial instrument). A loss allowance for full lifetime expected credit losses is required for a financial instrument if the credit risk of that financial instrument has increased significantly since initial recognition.

Deferred Taxes

Deferred tax assets and liabilities are recognized for deferred tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted or substantively enacted tax rates expected to apply when the asset is realized or the liability settled.

The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income (loss) in the period that substantive enactment occurs.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. To the extent that the Company does not consider it probable that a deferred tax asset will be recovered, the deferred tax asset is reduced.

4. CASH RESTRICTION

Upon successful completion of the IPO (see note 8), the proceeds raised from the issuance of share capital may only be used to identify and evaluate assets or businesses for future investment, with the exception that not more than $3,000 per month may be used for administrative expenses ofthe Company. These restrictions may apply until completion of the Qualifying Transaction by the Company as pursuant to the policies of the Exchange.

5. CAPITAL STOCK

Authorized

Unlimited number of common voting shares without nominal or par value.

Issued Common Shares

Issued share capital is as follows:

Shares issued for cash, December 31, 2020	-	2,001,281
Shares issued for cash, June 30, 2021	-	3,901,281

On April 14, 2021, the Company closed a non-brokered private placement of 1,900,000 common shares at a price of $0.05 per common share. No commission or finder's fees were paid in connection with the private placement.

5. CAPITAL STOCK (Cont'd)

All of the common shares upon successful completion of the IPO (see note 8) will be held in escrow until completion of a Qualifying Transaction. The escrowed common shares will be released as follows assuming listing on Tier 2 of the TSX Venture Exchange:

- 25% upon issuance of the Final Exchange Bulletin as defined under the policies of the Exchange; and,
- 25% on the dates that are 6, 12, and 18months following the date of the initial release.

Once the common shares are placed in escrow, they will be considered contingently issuable under IFRS until the Company completes a Qualifying Transaction and will not be considered outstanding for purpose of the earnings per share calculation.

Loss Per Share

The calculation of basic and diluted loss per share for the three months ended June 30, 2021 was based on the loss attributable to common shareholders of $16,795 (2020 - $21,876) and the average weighted average number of capital stock outstanding of 3,426,281 (2020 – 2,001,281).

6. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Capital Management

The Company's objective when managing capital is to maintain its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders.

The Company includes share capital in the definition of capital.

The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund the identification and evaluation of potential acquisitions. To secure the additional capital necessary to pursue these plans, the Company may attempt to raise additional funds through the issuance of equity or by securing strategic partners.

The Company is not subject to externally imposed capital requirements other than the cash restriction disclosed in Note 4.

Risk Disclosures and Fair Values

The Company's financial instruments, consisting of accrued liabilities, approximate fair values due to the relatively short term maturities of the instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

As at June 30, 2021, the Company had liabilities of $33,174 and had cash of $105,249 to meet its current obligations. As a result, the Company has minimal liquidity risk.

7. COVID-19

Since December 31, 2019, the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19", has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible to reliably estimate the length and severity of these developments and the impact they will have on the Company's financial position or on the successful completionof the IPO and QT, which may result in delays in the timing of closing of the IPO and QT.

8. SUBSEQUENT EVENTS

On August 24, 2021, the Company completed an IPO pursuant to which it issued an aggregate of 2,750,000 common shares at a price of $0.10 per common share for aggregate gross proceeds of $275,000, and net proceeds of $229,260. Following the completion of the IPO, there were 6,651,281 common shares issued and outstanding, 275,000 options granted to the Agent and 665,128 incentive stock options granted to the Company's directors and officers,of which 156,052 incentive stock options are exercisable into a common share at a price of $0.05 per share until June 11, 2031 and 509,076 incentive stock options are exercisable into a common share at a price of $0.10 per share until August 24, 2031.